Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
FAP-Ligands and Its Clinical Translation in Cancers
share announcement

FAP-Ligands and Its Clinical Translation in Cancers

A special issue of Cancers (ISSN 2072-6694).

Deadline for manuscript submissions: closed (31 March 2023) | Viewed by 8721

Special Issue Editors

Prof. Dr. Frederik L. Giesel

E-Mail Website
Guest Editor
Medical Faculty, University Hospital Düsseldorf, Heinrich Heine University, Düsseldorf, Germany
Interests: cancer imaging; cancer theranostic; FAP-ligands; PSMA-ligands; Alpha-/Beta-Therapies
Dr. Tadashi Watabe

E-Mail Website
Guest Editor
Osaka University Graduate School of Medicine, Suita, Japan
Interests: theranostics; molecular imaging; nuclear medicine
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

In this special issue, we are focusing on the new target with the scope of tumor micro-environment and its pathogenesis using radioligands in the field of nuclear medicine. Based on the recent introduction and translation of FAP-ligands, this special issue aims to promote further investigations in the field of FAPI-PET/CT in cancer and non-cancer diseases. Within the last years, FAP-ligands has been proven to play an important role for cancer detection, but also in pathological conditions  beyond oncology, FAP-ligands might also serve as additional important imaging surrogates in chronic inflammatory changes or even cardio-vascular diseases. Due to this exciting evolution of using FAP-ligand in the field of nuclear medicine, we would like to invite academic researchers and scientist to submit recent research results of FAP-ligands in diagnostic but also theranostic investigations.  

Nuclear medicine has been tremendously changed by the introduction of new ligands such as PSMA in conjunction with prostate cancer. Recently, novel innovative ligands beyond one tumor entity have emerged. Particulary, new FAP-ligands targeting tumor microenvironment (cancer associated fibroblasts) seem to be a highly promising evolution in the field of molecular imaging and therapy for its whole-cancer targeting. The aim of this special issue is to focus on the translational and clinical application of FAP-ligands in cancer and non-cancer diseases.

I/We look forward to receiving your contributions.

You may choose our Joint Special Issue in Current Oncology.

Prof. Dr. Frederik L. Giesel
Dr. Tadashi Watabe
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • FAP-ligands
  • FAPI
  • FAPI-PET
  • micro-stroma
  • nuclear medicine

Published Papers (4 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

20 pages, 2848 KiB  
Article
Subclass Analysis of Malignant, Inflammatory and Degenerative Pathologies Based on Multiple Timepoint FAPI-PET Acquisitions Using FAPI-02, FAPI-46 and FAPI-74
by Frederik M. Glatting, Jorge Hoppner, Hans-Ulrich Kauczor, Peter E. Huber, Clemens Kratochwil, Frederik L. Giesel, Uwe Haberkorn and Manuel Röhrich
Cancers 2022, 14(21), 5301; https://doi.org/10.3390/cancers14215301 - 28 Oct 2022
Cited by 9 | Viewed by 1836
Abstract
Purpose: FAPI-PET is a promising imaging technique for various malignant as well as non-malignant pathologies. In a recent retrospective analysis, we evaluated the diagnostic value of repetitive early FAPI-PET-imaging with FAPI-02, FAPI-46 and FAPI-74 for malignant, inflammatory/reactive and degenerative pathologies. Here, we apply [...] Read more.
Purpose: FAPI-PET is a promising imaging technique for various malignant as well as non-malignant pathologies. In a recent retrospective analysis, we evaluated the diagnostic value of repetitive early FAPI-PET-imaging with FAPI-02, FAPI-46 and FAPI-74 for malignant, inflammatory/reactive and degenerative pathologies. Here, we apply a subgroup analysis to that dataset and describe the tracer-wise uptake kinetic behavior of multiple types of FAPI-positive lesions, which are encountered frequently during clinical routine. Methods: A total of 24 cancer patients underwent whole-body FAPI-PET scans, and images were acquired at 10, 22, 34, 46 and 58 min after the administration of 150–250 MBq of 68Ga-FAPI tracer molecules (eight patients each regarding FAPI-02, FAPI-46 and FAPI-74). Standardized uptake values (SUVmax and SUVmean) of healthy tissues, cancer manifestations and non-malignant lesions were measured and target-to-background ratios (TBR) versus blood and fat were calculated for all acquisition timepoints. Results: Differential uptake behavior over time was observed in several subclasses of malignant lesions, inflammatory/reactive lesions and degenerative lesions. These differences over time were particularly manifested in the direct comparison between the uptakes associated with pancreatic carcinoma (stable or increasing over time) and inflammatory lesions of the pancreas (markedly decreasing over time). Furthermore, marked differences were found between the three tracer variants regarding their time-dependent uptake and TBRs within different subclasses of malignant, inflammatory/reactive and degenerative pathologies. Conclusion: Multiple timepoint FAPI-PET/CT is a promising innovative imaging technique that provides additional imaging information compared to single timepoint imaging. Differences in the kinetic behavior of malignant and benign pathologies can facilitate the interpretation of FAPI-positive lesions. Full article
(This article belongs to the Special Issue FAP-Ligands and Its Clinical Translation in Cancers)
►▼ Show Figures

Figure 1

14 pages, 1649 KiB  
Article
Evaluating the Combined Anticancer Response of Checkpoint Inhibitor Immunotherapy and FAP-Targeted Molecular Radiotherapy in Murine Models of Melanoma and Lung Cancer
by Kathleen M. Capaccione, Mikhail Doubrovin, Brian Braumuller, Dev Leibowitz, Nikunj Bhatt, Fatemeh Momen-Heravi, Andrei Molotkov, Michael Kissner, Kimberly Goldner, Mark Soffing, Alessandra Ali and Akiva Mintz
Cancers 2022, 14(19), 4575; https://doi.org/10.3390/cancers14194575 - 21 Sep 2022
Cited by 6 | Viewed by 2074
Abstract
Immunotherapy has dramatically improved outcomes for some cancer patients; however, novel treatments are needed for more patients to achieve a long-lasting response. FAP-targeted molecular radiotherapy has shown efficacy in both preclinical and clinical models and has immunomodulatory effects. Here, we studied if combined [...] Read more.
Immunotherapy has dramatically improved outcomes for some cancer patients; however, novel treatments are needed for more patients to achieve a long-lasting response. FAP-targeted molecular radiotherapy has shown efficacy in both preclinical and clinical models and has immunomodulatory effects. Here, we studied if combined immunotherapy and radiotherapy could increase antitumor efficacy in murine models of lung cancer and melanoma and interrogated the mechanisms by which these treatments attenuate tumor growth. Using LLC1 and B16F10 murine models of lung cancer and melanoma, respectively, we tested the efficacy of 177Lu-FAPI-04 alone and in combination with immunotherapy. Alone, 177Lu-FAPI-04 significantly reduced tumor growth in both models. In animals with melanoma, combined therapy resulted in tumor regression while lung tumor growth was attenuated, but tumors did not regress. Combined therapy significantly increased caspase-3 and decreased Ki67 compared with immunotherapy alone. Flow cytometry demonstrated that tumor-associated macrophages responded in a tumor-dependent manner which was distinct in animals treated with both therapies compared with either therapy alone. These data demonstrate that 177Lu-FAPI-04 is an effective anticancer therapy for melanoma and lung cancer which mediates effects at least partially through induction of apoptosis and modulation of the immune response. Translational studies with immunotherapy and 177Lu-FAPI-04 are needed to demonstrate the clinical efficacy of this combined regimen. Full article
(This article belongs to the Special Issue FAP-Ligands and Its Clinical Translation in Cancers)
►▼ Show Figures

Figure 1

12 pages, 7091 KiB  
Article
FAP-Specific Signalling Is an Independent Diagnostic Approach in ACC and Not a Surrogate Marker of MRI Sequences
by Dawn P. Liew, Manuel Röhrich, Lisa Loi, Sebastian Adeberg, Mustafa Syed, Ewgenija Gutjahr, Heinz Peter Schlemmer, Frederik L. Giesel, Martin Bendszus, Uwe Haberkorn and Daniel Paech
Cancers 2022, 14(17), 4253; https://doi.org/10.3390/cancers14174253 - 31 Aug 2022
Cited by 2 | Viewed by 1586
Abstract
Background: Fibroblast Activation Protein (FAP) is a new target for positron emission tomography and computed tomography (PET/CT) imaging of epithelial tumours embedded in a fibrous stroma. Adenoid cystic carcinomas (ACCs) have shown elevated tracer uptake in 68Gallium (68Ga)-labelled FAPIs in [...] Read more.
Background: Fibroblast Activation Protein (FAP) is a new target for positron emission tomography and computed tomography (PET/CT) imaging of epithelial tumours embedded in a fibrous stroma. Adenoid cystic carcinomas (ACCs) have shown elevated tracer uptake in 68Gallium (68Ga)-labelled FAPIs in previous studies. The current gold standard for ACC imaging is contrast-enhanced (ce) MRI, where intertumoural heterogeneity leads to variable appearance on T1-weighted (T1w) and T2-weighted (T2w) images. In this retrospective analysis, we correlated 68Ga-FAPI PET signalling at three time points with ceT1w and T2w MRI signals to further characterise the significance of 68Ga-FAPI uptake in ACCs. Methods: Clinical PET/CT scans of 12 ACC patients were performed at 10, 60 and 180 min post i.v. administration of 68Ga-labelled-FAPI tracer molecules. 68Ga-PET- and corresponding MRI-scans were co-registered, and 3D volumetric segmentations were performed on ceT1w and T2w lesions of co-registered MRI slides. Signal intensity values of 68Ga-FAPI PET signalling and ceT1w/T2w MRI scans were analysed for their pixelwise correlation in each patient. Pooled estimates of the correlation coefficients were calculated using the Fisher z-transformation. Results: 68Ga-FAPI PET signals showed a very weak positive correlation with ceT1w values (pooled correlation 0.114, 0.147 and 0.162 at 10, 60 and 180 min) and a weak negative correlation with T2w values (pooled correlation −0.148, −0.121 and −0.225 at 10, 60 and 180 min). Individual r-values at 60 min ranged from −0.130 to 0.434 in ceT1w and from −0.466 to 0.637 in T2w MRI scans. Conclusion: There are only slight correlations between the intensity of 68Ga-FAPI PET signals and tumour appearance in ceT1w or T2w MRI scans, which underlines that 68Ga-FAPI PET signalling is not a surrogate marker of MRI sequences but an independent signal. Full article
(This article belongs to the Special Issue FAP-Ligands and Its Clinical Translation in Cancers)
►▼ Show Figures

Figure 1

Review

Jump to: Research

10 pages, 431 KiB  
Review
Performance and Prospects of [68Ga]Ga-FAPI PET/CT Scans in Lung Cancer
by Paula E. Borgonje, Louise M. Andrews, Gerarda J. M. Herder and John M. H. de Klerk
Cancers 2022, 14(22), 5566; https://doi.org/10.3390/cancers14225566 - 13 Nov 2022
Cited by 6 | Viewed by 2409
Abstract
Fibroblast activation protein (FAP) could be a promising target for tumor imaging and therapy, as it is expressed in >90% of epithelial cancers. A high level of FAP-expression might be associated with worse prognosis in several cancer types, including lung cancer. FAPI binds [...] Read more.
Fibroblast activation protein (FAP) could be a promising target for tumor imaging and therapy, as it is expressed in >90% of epithelial cancers. A high level of FAP-expression might be associated with worse prognosis in several cancer types, including lung cancer. FAPI binds this protein and allows for labelling to Gallium-68, as well as several therapeutic radiopharmaceuticals. As FAP is only expressed at insignificant levels in adult normal tissue, FAPI provides a highly specific tumor-marker for many epithelial cancers. In this review, current information on the use of [68Ga]Ga-FAPI PET/CT in lung cancer is presented. [68Ga]Ga-FAPI shows a high uptake (standardized uptake value = SUVmax) and tumor-to-background ratio (TBR) in primary lung cancer lesions, as well as in metastatic lesions of other tumor types located in the lung and in lung cancer metastases located throughout the body. Where a comparison was made to [18F]FDG PET/CT, [68Ga]Ga-FAPI showed a similar or higher SUVmax and TBR. In brain and bone metastases, [68Ga]Ga-FAPI PET/CT outperformed [18F]FDG PET/CT. In addition to this strong diagnostic performance, a possible prognostic value of [68Ga]Ga-FAPI PET/CT in lung cancer is proposed. Full article
(This article belongs to the Special Issue FAP-Ligands and Its Clinical Translation in Cancers)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Back to TopTop